SCHEMBL3433741

SCHEMBL3433741

CCOC(=O)c1sc(N)nc1-c1nc(OC)cc(OC)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.60
HSD17B10 Q99714 4/20 0.60
CYP1A2 P05177 1/20 0.55
MAPT P10636 6/20 0.52
KDM4E B2RXH2 4/20 0.52
HPGD P15428 5/20 0.51
FBP1 P09467 1/20 0.51
LMNA P02545 2/20 0.46
ALOX15 P16050 1/20 0.44
POLB P06746 1/20 0.44
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
GAA P10253 3/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
TP53 P04637 1/20 0.43
CASP3 P42574 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3402018 0.85 ALDH1A1 (0.52) ALDH1A1HSD17B10MAPTKDM4EHPGD
SCHEMBL1505583 0.80 ALDH1A1 (0.67) ALDH1A1HSD17B10CYP1A2MAPTKDM4E
SCHEMBL28723241 0.78 ALDH1A1 (0.76) ALDH1A1HSD17B10CYP1A2MAPTKDM4E
SCHEMBL28719365 0.78 ALDH1A1 (0.64) ALDH1A1HSD17B10CYP1A2MAPTKDM4E
SCHEMBL17844015 0.77 ALDH1A1 (0.59) ALDH1A1HSD17B10CYP1A2MAPTKDM4E
SCHEMBL3406257 0.76 ALDH1A1 (0.58) ALDH1A1HSD17B10CYP1A2MAPTKDM4E
SCHEMBL28719271 0.75 ALDH1A1 (0.67) ALDH1A1HSD17B10CYP1A2MAPTKDM4E
SCHEMBL330552 0.75 ALDH1A1 (1.00) ALDH1A1HSD17B10CYP1A2MAPTKDM4E
SCHEMBL930118 0.74 ALDH1A1 (0.56) ALDH1A1HSD17B10CYP1A2MAPTKDM4E
SCHEMBL17844007 0.73 ALDH1A1 (0.62) ALDH1A1HSD17B10CYP1A2MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2158199-B1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2010-11-17 EP disclosed
EP-2158199-B1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2010-11-17 EP disclosed
WO-2008152418-A1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2008-12-18 WO disclosed
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 ASTRAZENECA AB (SE) 2008-12-18 US disclosed
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 ASTRAZENECA AB (SE) 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 NISCH, PIR, QDPR ALDH1A1 243/4885HSD17B10 4653/4885CYP1A2 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.